Repare Therapeutics Inc. shareholders have approved the acquisition by XenoTherapeutics, Inc.
The acquisition includes all of the issued and outstanding common shares of Repare Therapeutics Inc.
The approval was achieved through a special meeting of shareholders and a high percentage vote in favor.
The approval by shareholders indicates strong support for the acquisition, paving the way for strategic developments with XenoTherapeutics, Inc.
Shareholders Approval
A significant 99.76% of the votes cast by shareholders approved the Arrangement, showcasing overwhelming support for the acquisition deal.
Compensation Approval
99.34% of shareholders approved the compensation for executive officers related to the Arrangement, signaling confidence in the proposed terms.
Liquidation Approval
A notable 99.75% of shareholders supported the voluntary liquidation and dissolution of the Company in case the Arrangement is terminated, indicating preparedness for all scenarios.
Arrangement Completion Date
The expected completion date of the Arrangement is on or about January 28, 2026, setting a timeline for the finalization of the acquisition deal.
- The high percentage of shareholder approval demonstrates robust backing for the acquisition, hinting at a positive sentiment towards the strategic direction of the combined entities.
- The completion of the Arrangement is contingent upon the approval of the Superior Court of Québec and other closing conditions, highlighting the regulatory and procedural steps remaining before finalizing the acquisition.
The approval by Repare Therapeutics Inc. shareholders for the acquisition by XenoTherapeutics, Inc. marks a pivotal moment for the company, laying the groundwork for future collaborations and growth opportunities with the acquiring entity.